Employing a therapeutic approach to augment the migratory population of cDC1s by combining Fms-related tyrosine kinase 3 ligand with an agonistic CD40 antibody has been shown to promote SlamF6+TCF-1+ CD8 stimulation in dLN, subsequently resulting in enhanced T-cell trafficking into tumors and a reduction in tumor burden [76]. This evidence concerns the gene CD40 and neoplasm.